Topics
Business & Finance
-
Monday - February 20, 2012
Not intended for U.S. and UK Media
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye » more
-
Wednesday - January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation » more
-
Wednesday - January 18, 2012
Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) » more
-
Tuesday - January 10, 2012
Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 » more
-
Thursday - December 29, 2011
Not intended for U.S. and UK Media - Submission in New Indication:
Bayer’s Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome » more
-
Thursday - December 22, 2011
Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy » more
-
Tuesday - December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again » more
-
Monday - December 19, 2011
For use outside the US and UK only
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT) » more
-
Wednesday - December 14, 2011
For use outside the US and UK only
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
Once approved, the new low dose IUS will offer young women contraception for up to three years » more
-
Friday - December 9, 2011
Not intended for U.S. and UK media: Bayer’s drospirenone-containing combination oral contraceptives:
FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies » more
-
Monday - November 28, 2011
Not intended for U.S. and UK Media
Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China » more
-
Friday - November 18, 2011
Not intended for U.S. and UK Media
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials / Regeneron Pharmaceuticals will market EYLEA™ in the U.S. » more
-
Wednesday - November 16, 2011
“Perspective on Growth in Asia”
Bayer plans further expansion in Asia
Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai » more
-
Sunday - November 13, 2011
Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Rivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both the Rate of Cardiovascular Death and the Incidence of All-Cause Mortality by more than 30% / Major Bleeding in Patients Receiving Rivaroxaban was Significantly Increased but there was no Increase in the Risk of Fatal Bleeding / Study Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association and Published by the New England Journal of Medicine » more
-
Friday - November 4, 2011
Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke prevention in patients with atrial fibrillation / Rivaroxaban does not require routine coagulation monitoring, making it more convenient to both patients and physicians » more
-
Thursday - October 27, 2011
Bayer AG Third Quarter 2011 Results and News Conference Call » more
-
Thursday - October 27, 2011
News Conference Call for the Third Quarter of 2011
Address by Dr. Marijn Dekkers
Chairman of the Board of Management » more
-
Thursday - October 27, 2011
After a good third quarter: Bayer confirms Group outlook
Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR 1,099 million / EBITDA before special items up by 8.5 percent to EUR 1,805 million / HealthCare and CropScience margins distinctly improved – MaterialScience weaker / Net income more than doubled to EUR 642 million (plus 125.3 percent) » more
-
Wednesday - October 26, 2011
Not intended for U.S. and UK media
Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Trial stopped based on positive data from a pre-planned interim analysis » more
-
Wednesday - October 12, 2011
Not intended for U.S. and UK media
Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
Settlement in Litigation Reached » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection